Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATISSE 2 nivolumab organ-preservation study in cutaneous squamous cell carcinoma
NL-OMON59149Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical complete remission rate. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NL-OMON59149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59149.